ARLG Spotlight – Clinical Operations Project Leader and ARLG Laboratory Center Liaison Carol Hill Retiring
What is your full name, title, role, and institution? Carol Bova Hill, ARLG Laboratory Center Liaison – Clinical Operations Project Leader, Duke Clinical Research Institute How many years have you worked on ARLG projects? I have worked on the ARLG since the initial grant submission effort and subsequent startup in 2013 as a member of the Laboratory Center ...Read moreECCMID 2024: Featured ARLG Sessions and Posters
It’s that time of year again! ECCMID 2024 is here and many of ARLG’s top leaders and experts are featured, discussing the latest AR topics. Whether you plan to attend virtually or in person, use the table below to plan ahead to join your favorite sessions and posters. Learn more and view OnDemand content at ECCMID.orgRead moreARLG Spotlight – Clinical Trials Specialist (CTS) Ivra Bunn Retiring
What is your full name, title, role, and institution? Ivra Bunn, Clinical Trials Specialist (CTS), Duke Clinical Research Institute How many years have you worked on ARLG projects? I have been with ARLG for the 11 years that it has been in existence. ARLG was created in 2013. It was just 3 of us on this project at ...Read moreARLG Member, Eli Perencevich, MD, MS, Named Editor in Chief of JAMA Network Open
Eli Perencevich, MD, MS has been named editor in chief of JAMA Network Open! JAMA Network announced Dr. Perencevich’s appointment on March 20; he will succeed the founding Editor in Chief, Frederick P. Rivara, MD, MPH on July 1, 2024. Dr. Perencevich currently serves as an Associate Editor for JAMA Network Open. He is the Associate ...Read more
ARLG in the News
As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest, JAMA Network, February 22, 2023
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection, January 12, 2023
Study Evaluates Biomarker to Help Curb Unnecessary Antibiotic Use, December 13, 2022
NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins, October 4, 2022
Dr. Robin Patel Selected for 2022 Hamao Umezawa Memorial Award, March 8, 2022
Local VA Infectious Disease Expert Selected to Lead Emerging Infectious Diseases Response, March 2, 2022
Duke doctor: Superbugs are the next pandemic. What the US must do to combat them. Op-ed, Raleigh News & Observer, Charlotte Observer, Durham Herald-Sun. January 20, 2022
Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study, November 2, 2021
Carbapenem-resistant Enterobacterales in the USA, March 6, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study, March 6, 2020
NIH Renews Funding for the Antibacterial Resistance Leadership Group, NIAID, December 13, 2019
Research Network Based at DCRI Awarded up to $102.5M for Work on Antibacterial Resistance, DCRI, December 13, 2019
Duke Clinical Research scores $102.5M federal award for its work on antibacterial resistance, WRAL TechWire, December 2019.
Duke Clinical Research Institute lands $100M+ federal contract, Triangle Business Journal, December 2019.
Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhea and Chlamydia: Innovative Science and a Call to Arms. Clinical Infectious Diseases editorial authors praise the ARLG MASTER-GC study for its clinical relevance and collaborative approach to the development of diagnostics. November 2019.
Reviewing data collected by the ARLG, FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea, FDA, May 23, 2019
The ARLG and COMBACTE join forces to create gloabal alliance against antibiotic resistance, DCRI, April 13, 2019
Antibiotic Resistance in the News
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, The Lancet, January 19, 2022
Pull Incentives for Antibiotics: How Much and Why? April 2020
IDWeek announces new June 18 deadline extension for abstract submissions April 2020
Antibiotic resistance: the hidden threat lurking behind COVID-19 March 2020
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization February 2020
Centers for Disease Control and Prevention releases its 2019 Antibiotic Resistance Threats Report, CDC November 2019
Wellcome Trust releases report on Reframing Resistance—How to communicate about antimicrobial resistance effectively, October 2019
Too many people use antibiotics improperly, which can pose risks, (featuring Vance Fowler, MD) Washington Post, September 16, 2019